Julie Krop - Newton MA, US Marilyn Pike - Cambridge MA, US Dean Falb - Wellesley MA, US Bret Shirley - Waltham MA, US Denis Schrier - Hopkinton MA, US Mary Elizabeth Goad - Andover MA, US
International Classification:
A61K 38/18 A61P 29/00 A61P 19/08
US Classification:
514 88
Abstract:
Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis. The methods of the invention provide long-term pain relief to sufferers of osteoarthritis and can improve the functionality of the joint to which the BMP is administered.
Julie Krop, chief medical officer for AMAG Pharmaceuticals Inc., which makes the drug, recommends using it about 45 minutes before the "anticipation" of intimacy. She said the drug is a synthetic hormone that activates key brain receptors involved in sexual responses by reducing inhibition and incre
broadening the indication for Feraheme to include all patients with iron deficiency anemia. This safety trial represents a significant step forward in that process," said Dr. Julie Krop, chief medical officer and senior vice president of clinical development and regulatory affairs at AMAG. "Approximately 4.